ScanSource
SCSC
59.68
-1.26
-2.07%
ScanSource
US · SCSC
#3107 by market cap
Listed 1970
59.68
-1.26
-2.07%
Live - 5344 symbols - heartbeat 205s ago
· 2026-10-08 07:40
Pre-market
58.80
-1.47%
After-hours
59.65
-0.05%
- Market cap
- 1.20B
- P/E (TTM)i
- 16.40
- P/Bi
- 1.32
- EPSi
- 3.64
- Div yieldi
- 0.00%
- 52W posi
- 78%
Reader sentiment
Are you bullish or bearish on SCSC?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 3.69, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +6.09% YoY
Margins
- Gross margin
- 13.56%
- Operating margin
- 3.15%
- Net margin
- 2.44%
Key ratios & quality
- Enterprise valuei
- 1.22B
- Altman Z-Scorei
- 3.69
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 3.25B | 3.05B | 3.15B | 3.53B | 3.79B | 3.26B | 3.04B | 3.23B |
| Gross profit | 392.80M | 355.57M | 350.72M | 426.52M | 449.24M | 399.05M | 408.65M | 437.36M |
| Selling & admin expenses | 244.29M | 259.54M | 247.44M | 275.44M | 285.70M | 277.43M | 286.93M | 313.18M |
| Research & development | -- | -- | -- | -- | -- | -- | -- | -- |
| Operating profit | 118.59M | 63.05M | 71.26M | 122.17M | 135.89M | 94.68M | 92.48M | 101.47M |
| Pretax profit | 83.64M | -71.78M | 57.54M | 118.62M | 121.85M | 99.84M | 94.40M | 103.74M |
| Tax | 18.78M | 7.45M | 12.15M | 29.93M | 33.76M | 22.78M | 22.85M | 24.87M |
| Net profit | 57.60M | -192.65M | 10.80M | 88.80M | 89.81M | 77.06M | 71.55M | 78.87M |
| Basic EPS | 2 | -8 | 0 | 3 | 4 | 3 | 3 | 4 |
| Diluted EPS | 2.24 | -7.59 | 0.42 | 3.45 | 3.54 | 3.06 | 3.00 | 3.64 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 704.85M | 812.89M | 739.65M | 766.51M | 766.79M | 953.11M |
| Gross profit | 100.20M | 105.10M | 107.47M | 102.91M | 107.12M | 119.85M |
| Selling & admin expenses | 69.70M | 71.61M | 75.28M | 78.11M | 78.07M | 81.72M |
| Research & development | -- | -- | -- | -- | -- | -- |
| Operating profit | 23.24M | 26.64M | 26.22M | 19.08M | 23.56M | 32.61M |
| Pretax profit | 24.23M | 27.50M | 27.00M | 19.42M | 24.05M | 33.27M |
| Tax | 6.80M | 7.41M | 7.12M | 2.93M | 7.17M | 7.66M |
| Net profit | 17.43M | 20.09M | 19.88M | 16.49M | 16.89M | 25.62M |
| Basic EPS | 1 | 1 | 1 | 1 | 1 | 1 |
| Diluted EPS | 0.74 | 0.87 | 0.89 | 0.75 | 0.78 | 1.24 |
Balance sheet
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 1.48B | 1.20B | 1.22B | 1.52B | 1.66B | 1.40B | 1.37B | 1.51B |
| Cash & ST investments | 19.31M | 29.49M | 62.72M | 37.99M | 36.18M | 185.46M | 126.16M | 88.37M |
| Inventory | 554.08M | 454.89M | 470.08M | 614.81M | 757.57M | 512.63M | 483.82M | 522.35M |
| Total assets | 2.07B | 1.69B | 1.67B | 1.94B | 2.07B | 1.78B | 1.79B | 1.93B |
| Total current liabilities | 700.89M | 719.01M | 732.94M | 814.26M | 786.80M | 669.35M | 682.96M | 859.14M |
| Short-term debt | 4.09M | 12.32M | 12.13M | 16.10M | 11.27M | 11.26M | 11.85M | 7.42M |
| Long-term debt | 323.40M | 210.89M | 135.33M | 259.57M | 322.99M | 136.20M | 128.29M | 98.55M |
| Total liabilities | 1,153,132,000.00 | 1,013,848,000.00 | 940,493,000.00 | 1,130,900,000.00 | 1,162,871,000.00 | 854,777,000.00 | 879,197,000.00 | 1,021,637,000.00 |
| Total equity | 914.13M | 678.25M | 731.19M | 806.53M | 905.30M | 924.26M | 906.41M | 910.79M |
| Retained earnings | 939.93M | 747.28M | 758.07M | 846.87M | 936.68M | 1.01B | 1.02B | 1.02B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 1.31B | 1.37B | 1.31B | 1.30B | 1.37B | 1.51B |
| Cash & ST investments | 146.29M | 126.16M | 124.92M | 83.47M | 120.30M | 88.37M |
| Inventory | 476.21M | 483.82M | 505.34M | 490.26M | 486.63M | 522.35M |
| Total assets | 1.73B | 1.79B | 1.72B | 1.74B | 1.81B | 1.93B |
| Total current liabilities | 631.85M | 682.96M | 606.16M | 664.23M | 736.81M | 859.14M |
| Short-term debt | 7.86M | 11.85M | 7.87M | 2.87M | 2.87M | 7.42M |
| Long-term debt | 130.16M | 128.29M | 126.05M | 99.80M | 99.17M | 98.55M |
| Total liabilities | 823,462,000.00 | 879,197,000.00 | 802,944,000.00 | 830,785,000.00 | 899,495,000.00 | 1,021,637,000.00 |
| Total equity | 901.75M | 906.41M | 914.03M | 910.89M | 906.26M | 910.79M |
| Retained earnings | 1.02B | 1.02B | 1.02B | 1.03B | 1.01B | 1.02B |
Cash flow
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -27.13M | 178.11M | 87.27M | -124.35M | -35.77M | 371.65M | 112.35M | 123.13M |
| Depreciation & amortization | 33.65M | 35.33M | 33.51M | 29.88M | 28.61M | 28.01M | 30.20M | 23.63M |
| Free cash flow | -32.92M | 171.73M | 84.91M | -131.20M | -45.75M | 363.09M | 104.06M | 113.85M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -9.48M | -6.08M | 0 | -18.20M | -15.65M | -42.90M | -106.52M | -97.90M |
| Ending cash balance | 23.82M | 34.46M | 62.72M | 37.99M | 36.18M | 185.46M | 126.16M | 88.37M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | 66.06M | 7.65M | 23.21M | 30.84M | 71.35M | -2.27M |
| Depreciation & amortization | 7.49M | 7.10M | 6.20M | 5.94M | 5.71M | 5.78M |
| Free cash flow | 64.64M | 5.13M | 20.82M | 28.87M | 68.95M | -4.79M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -28.92M | -25.27M | -21.29M | -17.40M | -32.70M | -26.52M |
| Ending cash balance | 146.29M | 126.16M | 124.92M | 83.47M | 120.30M | 88.37M |
Returns & efficiency
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | 6.47 | -24.20 | 1.53 | 11.55 | 10.49 | 8.42 | 7.82 | 8.68 |
| ROA %i | 2.87 | -10.25 | 0.64 | 4.92 | 4.48 | 4.01 | 4.01 | 4.24 |
| ROIC %i | 5.53 | -17.11 | 1.52 | 9.09 | 8.43 | 6.87 | 6.48 | 7.19 |
| 5-year avg ROE %i | 7.02 | 0.56 | -0.74 | -0.15 | 1.17 | 1.56 | 7.96 | 9.39 |
| EBIT margin %i | 2.36 | -1.95 | 2.05 | 3.55 | 3.74 | 3.46 | 3.37 | 3.42 |
| FCF / sales %i | -- | 7.21 | 4.40 | -- | -- | 11.14 | 3.42 | 3.53 |
| Current ratioi | 2.11 | 1.67 | 1.66 | 1.87 | 2.11 | 2.10 | 2.01 | 1.76 |
| Quick ratioi | 0.86 | 0.74 | 0.97 | 1.03 | 1.11 | 1.30 | 1.26 | 1.11 |
| Debt / assetsi | 15.84 | 14.42 | 9.81 | 14.90 | 16.61 | 8.65 | 8.24 | 5.74 |
| LT debt / equityi | 35.38 | 34.15 | 20.77 | 33.81 | 36.71 | 15.44 | 14.92 | 11.36 |
| Interest coveragei | 6.82 | -4.87 | 9.30 | 19.19 | 7.16 | 8.66 | 12.78 | 16.74 |
| Revenue CAGR (3Y) %i | -2.81 | -5.12 | -0.15 | 2.79 | 7.51 | 1.14 | -4.85 | -5.21 |
| Net income CAGR (3Y) %i | -3.26 | -- | -31.20 | 15.52 | -- | 92.55 | -6.95 | -4.24 |
| FCF CAGR (3Y) %i | -- | 27.71 | 68.31 | -- | -- | 62.31 | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | 7.32 | 7.82 | 8.12 | 8.16 | 8.11 | 8.68 |
| ROA %i | 3.85 | 4.01 | 4.25 | 4.29 | 4.15 | 4.24 |
| ROIC %i | 6.10 | 6.48 | 6.77 | 6.85 | 6.81 | 7.19 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | 3.28 | 3.37 | 3.54 | 3.50 | 3.41 | 3.42 |
| FCF / sales %i | 5.12 | 3.42 | 2.74 | 3.95 | 4.01 | 3.53 |
| Current ratioi | 2.07 | 2.01 | 2.16 | 1.96 | 1.86 | 1.76 |
| Quick ratioi | 1.12 | 1.26 | 1.13 | 1.04 | 1.02 | 1.11 |
| Debt / assetsi | 8.00 | 8.24 | 7.80 | 5.89 | 5.65 | 5.74 |
| LT debt / equityi | 14.43 | 14.92 | 13.79 | 10.96 | 10.94 | 11.36 |
| Interest coveragei | 12.20 | 12.78 | 13.59 | 13.59 | 14.49 | 16.74 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
✦ Quant Revenue Concentration how this is computed
Single-engine
- Specialty Technology Solutions is the largest reported line at 96.87% of revenue, across 2 reported segments.
- The next-largest line, Intelisys & Advisory, is a distant second at 3.13% - a sharp slowdown here would have little to offset it.
Revenue breakdown most recent period
Business
Specialty Technology Solutions96.87%
Intelisys & Advisory3.13%
Region
United States93.09%
Brazil7.05%
Quote time 2026-10-08 07:40:56 · For reference only, not investment advice and not tailored to your situation.